Dilraj Grewal, MD
Ophthalmology · Chicago, ILNPI 1437460656
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $153,444 of the $187,906 with a category attached, or 81.7%. 24 manufacturers reported payments, led by Astellas Pharma Global Development at 33.2% of the total. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 127 payments — averaging $1479.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma Global Development$62K
- Regeneron$59K
- Chugai Pharmaceutical Co., Ltd.$19K
- Dutch Ophthalmic, USA$12K
- Eyepoint US, Inc.$10K
- Apellis Pharmaceuticals, Inc.$8K
- plus $18K from 18 others
Across 91 payments — averaging $4377.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$185K
- Gilead$88K
- Eyepoint US, Inc.$71K
- Regeneron$31K
- Astellas Pharma Global Development$23K
- Novartis$1K
What the payments were for
- Consulting fees$153,44482%
- Speaking & faculty fees$2,5631%
- Travel & lodging$27,27815%
- Food & beverage$4,5962%
- Education$60%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma Global Development | 18 | $62,308 |
| Regeneron | 11 | $58,783 |
| Chugai Pharmaceutical Co., Ltd. | 3 | $18,767 |
| Dutch Ophthalmic, USA | 7 | $11,803 |
| Eyepoint US, Inc. | 14 | $9,714 |
| Apellis Pharmaceuticals, Inc. | 7 | $8,484 |
| Bausch & Lomb Americas Inc. | 10 | $5,083 |
| Alimera Sciences, Inc. | 5 | $2,822 |
| F. Hoffmann-la Roche AG | 2 | $2,128 |
| Genentech USA, Inc. | 2 | $2,050 |
| AbbVie(2 entities) | 5 | $1,816 |
| Dutch Ophthalmic Research Center (international) B.v. | 16 | $1,231 |
| Carl Zeiss Meditec, Inc. | 4 | $1,056 |
| Carl Zeiss Meditec USA, Inc. | 7 | $638 |
| Alcon | 3 | $398 |
| Heidelberg Engineering, Inc. | 1 | $205 |
| Genentech, Inc. | 2 | $195 |
| Novartis | 3 | $132 |
| Regeneron Healthcare Solutions, Inc. | 1 | $111 |
| Topcon Healthcare, Inc. | 2 | $86 |
| Neurotech Pharmaceuticals, Inc. | 1 | $38 |
| Ocular Therapeutix, Inc. | 1 | $27 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Aerie Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Izervay$62,168
- EYLEA$49,952
- EVA, combined machine$12,189
- TISSUEBLUE$12,189
- YUTIQ$9,998
- XIPERE$4,729
- Syfovre$3,907
- Lucentis$1,980
- DEXYCU$1,500
- OZURDEX$1,101
- EYP-1901$1,047
- Iluvien$1,000
- CIRRUS HD-OCT$810
- Humphrey HFA$810
- IOLMaster 700$810
- VERACITY SURGICAL$810
- VisuMax$810
- EVA Ophthalmic Surgical System$500
- Spectralis$205
- AcrySof IQ PanOptix$187
How this compares
$187,906 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 359 | $16,152 |
| Difluprednate | 41 | $5,259 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $5,092 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 278 | $4,437 |
| Alphagan PBrimonidine Tartrate | 18 | $3,858 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $3,851 |
| Latanoprost | 327 | $3,329 |
| LumiganBimatoprost | 11 | $3,071 |
| Timolol Maleate | 95 | $2,635 |
| Bromfenac Sodium | 12 | $2,260 |
| Brimonidine Tartrate | 162 | $1,901 |
| ValacyclovirValacyclovir Hcl | 35 | $1,619 |
| Atropine Sulfate | 56 | $1,471 |
| Dorzolamide Hcl | 38 | $567 |
| ErythromycinErythromycin Base | 49 | $492 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Alphagan P, Lumigan | $1,816 | $12,02040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Surendra BastiChicago$126K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
- Robison ChanChicago$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.